Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
Genmab pushes rina-S into its third phase 3
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
ESMO 2025 preview – Astra joins the folate fray
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
Incyte goes pivotal in CDK2
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
NextCure joins Merck in an ovarian target
But the former is paying a fraction of what Merck shelled out for raludotatug.
